Succinylcholine (Quelicin,
Anectine) |
Category:
Description:
Indications:
Contraindications:
-
Patients
with genetically determined disorders of plasma pseudocholinesterase
-
Personal
or family history of malignant hyperthermia
-
Myopathies
associated with elevated creatine phosphokinase values
-
Acute
narrow-angle glaucoma
-
Penetrating
eye injuries
Precautions:
-
Pregnancy
category C
-
Only
used by skilled personnel in airway management and respiratory
support.
-
Must
have anticholinesterase reversal agents immediately available during
use.
-
Use
with caution in patients with cardiovascular, hepatic, pulmonary,
metabolic or renal dysfunction.
-
Use
with caution in patients with severe burns and electrolyte imbalances.
-
Prolonged
blockade may occur in patients who are hypokalemic, hypocalcemic, or
having hepatic, cardiovascular or pulmonary disorders.
-
Produces
a slight, transient increase in intraocular and intracranial pressure.
-
May
cause malignant hyperthermia in susceptible patients.
-
Will
cause histamine release. Use
with caution in patients susceptible to histamine, such as
cardiovascular disease and asthma.
-
Contains
benzyl alcohol that may cause “gasping syndrome” in premature
infants.
-
May
cause bradycardia during anesthesia.
-
Use
with caution in patients with neuromuscular disease.
-
Use
a peripheral nerve stimulator to monitor twitch suppression and
recovery.
Adverse
Reactions (Side Effects):
-
Cardiovascular:
hypotension, vasodilation, tachycardia, bradycardia, cardiac arrest
-
Respiratory
depression and apnea
-
Malignant
hyperthermia, increased intraocular pressure, muscle twitching,
post-operative muscle pain
-
Excessive
salivation
|
Dosage:
· Administered via IV or IM injection
· Initiate therapy only after patient is unconscious.
· Short surgery: 0.6mg/kg IV (paralysis lasts 2 minutes, recovery 4-6
minutes)
· Long surgery: 2.5-4.3mg/min (commonly 1-2mg/mL infused as constant IV
drip)
· Prolonged relaxation (mechanical ventilation): 0.3-1.1mg/kg initial, then
0.04-0.07mg/kg administered to maintain relaxation as IV infusion
· Children:
- young children: 2mg/kg IV
- older children: 1mg/kg IV
- IM (in absence of suitable vein): 3-4mg/kg (not to exceed 150mg)
|
|
|
|
The information contained here is an
abbreviated summary. For more detailed and complete information, consult the
manufacturer's product information sheets or standard textbooks
Source: Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington,
D.C., 20372-5300
This information is provided by The Brookside Associates. The Brookside
Associates, LLC. is a private organization, not affiliated with any governmental
agency. The opinions presented here are those of the author and do not
necessarily represent the opinions of the Brookside Associates or the Department
of Defense. The presence of any advertising on these pages does not constitute
an endorsement of that product or service by either the US Department of Defense
or the Brookside Associates. All material presented here is unclassified.
C. 2009, 2014, All Rights Reserved
|
|